Pharmacy Medical News about Breast Neoplasms

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK
PharmacoEconomics, 10/12/09

Benedict A et al. – In the base–case scenario, docetaxel compared with Pac3w is estimated to have a cost–effectiveness ratio that falls within the acceptable threshold in the UK. The study also suggests that docetaxel may be cost effective versus Pac1w and Nab–P, although there is more uncertainty around these findings.

<< Previous
A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran...

Next >>
Apoptosis induction effects of EGCG in laryngeal squamous cell...

Sinusal localization of nodal micrometastases is a prognostic factor in breast cancer
Annals of Oncology, 11/04/09 Relevance Score: 67%

Energy Intake and Risk of Postmenopausal Breast Cancer: An Expanded Analysis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort
Cancer Epidemiology, Biomarkers & Prevention, 10/23/09 Relevance Score: 67%

Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging
The American Journal of Surgery, 10/07/09 Relevance Score: 67%

The predictive value of incidental PET/CT findings suspicious for breast cancer in women with non-breast malignancies
The American Journal of Surgery, 10/06/09 Relevance Score: 67%

A case–control study of reproductive factors associated with subtypes of breast cancer in Northeast China
Medical Oncology, 10/01/09 Relevance Score: 67%